Biomason

About:

Biomason is a developer of a building materials technology that employs natural microorganisms to grow bio cement in ambient temperatures.

Website: http://biomason.com/

Twitter/X: biomason

Top Investors: Hartree Partners, National Science Foundation, Novo Holdings, Celesta Capital, 2150

Description:

Biomason is a developer of a building materials technology to produce biological cement-based building materials alternatives. Its bio cement production combines natural microorganisms and chemical processes to develop masonry materials at room temperature, which helps replace traditional clay and concrete, and the high energy consumption associated with standard manufacturing them, enabling builders to acquire alternative building materials that are produced carbon-free. Since 2012, the company has used microorganisms to grow sustainable, structural biocement® in ambient temperatures, harnessing the power of biotechnology to reinvent traditional cement and offer a planet-friendly alternative. Biocement will eliminate 25% of the concrete industry’s global carbon emissions by 2030. Biomason bio cement is in use in projects throughout the US and Europe, and bioLITH precast tile products are commercially available.

Total Funding Amount:

$95M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Durham, North Carolina, United States

Founded Date:

2012-01-01

Contact Email:

hello(AT)biomason.com

Founders:

Ginger Krieg Dosier, Michael Dosier

Number of Employees:

51-100

Last Funding Date:

2022-02-28

IPO Status:

Private

Industries:

© 2025 bioDAO.ai